Connect with us

Press Releases

RxSight Announces Pricing of Public Offering of Common Stock

RxSight expects to sell 4,000,000 shares of its common stock at a price to the public of $12.50 per share.

mm

Published

on

(PRESS RELEASE) ALISO VIEJO, CA — (NASDAQ: RXST) – RxSight, Inc. (“RxSight”), an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced that it has priced its underwritten public offering. RxSight expects to sell 4,000,000 shares of its common stock at a price to the public of $12.50 per share. RxSight has granted the underwriter a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by RxSight. Before deducting the underwriting discount and estimated offering expenses payable by RxSight, RxSight expects to receive gross proceeds of approximately $50.0 million, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about February 10, 2023 subject to satisfaction of customary closing conditions. BofA Securities is acting as the sole bookrunning manager for the offering.

RxSight intends to use the net proceeds from the offering for continued commercial and marketing expansion, funding of product development, research and clinical development, and for working capital and general corporate purposes.

RxSight filed a shelf registration statement on Form S-3 relating to the shares of common stock offered in the public offering described above with the Securities and Exchange Commission (the “SEC”) on August 8, 2022, which was declared effective by the SEC on August 12, 2022. RxSight has filed a preliminary prospectus supplement and accompanying prospectus relating to the offering with the SEC on February 7, 2023. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC and will be available on the SEC’s website here. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained from: BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, by telephone at 1-800-294-1322 or by email at dg.prospectus_requests@bofa.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. The offering may be made only by means of a prospectus supplement and accompanying prospectus.

SPONSORED VIDEO

Get the Practice of Your Dreams With Omg! Optical Marketing Group

This high volume practice had outgrown their ultra successful location and needed expansion. The idea was big, just like Texas! Design a fusion concept that featured optometry, aesthetics, fitness + wellness. Mission accomplished. Download the Free Lookbook.

Promoted Headlines

Most Popular